Abstract
Alzheimer's disease (AD) is a widespread neurodegenerative disorder with complex causes. Starting with a historical overview, this paper traces the foundational discoveries by Alois Alzheimer and subsequent research into the roles of Tau, beta-amyloid (Aß), and cellular prion protein (PrPc) in AD progression. The familial aspect of AD is discussed, highlighting genetic mutations in key genes such as APP, PSEN1, PSEN2, MAPT, and APOE. Additionally, it explores epigenetic factors in familial AD and examines the prion-like behavior of Tau and Aß proteins. Potential therapeutic targets arising from these insights are considered, including PRNP manipulation and modulation of Tau and Aß behavior. A proposed stem cell therapy aims to target and counteract the pathological activities of Tau and Aß proteins through strategic genetic modifications, precise delivery to affected brain regions, and controlled release systems for sustained therapeutic effects. Ethical considerations and limitations in AD research are also addressed, emphasizing the importance of responsible research practices and equitable access to treatments. Through this exploration, the text underscores the ongoing efforts to unravel the complexities of AD and develop effective strategies for its management.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
